Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Rubinstein

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2019
Exposure time versus cytotoxicity for anticancer agentsDavid M Evans, Jianwen Fang, Thomas Silvers, et al.
Nature Reviews. Cancer|January 26, 2007
Compressing drug development timelines in oncology using phase '0' trialsShivaani Kummar, Robert Kinders, Larry Rubinstein, et al.
JNCI Cancer Spectrum|December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experienceJoaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Phase 0 clinical trials: conceptions and misconceptionsShivaani Kummar, Larry Rubinstein, Robert Kinders, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2019
Exposure time versus cytotoxicity for anticancer agentsDavid M Evans, Jianwen Fang, Thomas Silvers, et al.
Nature Reviews. Cancer|January 26, 2007
Compressing drug development timelines in oncology using phase '0' trialsShivaani Kummar, Robert Kinders, Larry Rubinstein, et al.
JNCI Cancer Spectrum|December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experienceJoaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Phase 0 clinical trials: conceptions and misconceptionsShivaani Kummar, Larry Rubinstein, Robert Kinders, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Pageof 6